University of Dundee

Professor Sir Mike Ferguson CBE FRS FRSE FMedSci FRSB

Molecular parasitology, glycobiology and drug discovery
Regius Professor of Life Sciences
School of Life Sciences, University of Dundee, Dundee
Full Telephone: 
+44 (0) 1382 386672, int ext 86672


Mike Ferguson is Regius Professor of Life Sciences in the School of Life Sciences. On 5 November 2021, he was elected as an academic member of Staff Council to serve a four-year term on Court, running to 31 July 2025.

Mike Ferguson obtained a PhD in Biochemistry (1982) at London University. He was a Postdoctoral Fellow at the Rockefeller University, New York, with George Cross FRS and at Oxford University with Raymond Dwek FRS. He took up a lectureship at The University of Dundee in 1988 and was promoted to a personal chair in Molecular Parasitology in 1994 and was appointed the first Regius Professor of Life Sciences in 2013.

He has published over 250 peer reviewed research papers and is known for solving the first structures of glycosylphosphatidylinositol (GPI) membrane anchors, which play important roles throughout eukaryotic biology.

His research takes a multidisciplinary approach to understanding the biochemistry of protozoan parasites that cause tropical diseases, particularly the trypanosomatids that cause human African Sleeping Sickness, Chagas' disease and leishmaniasis. He believes in the fundamental importance of working across the Biology / Chemistry interface and is particularly interested in Translational Research. Together with his colleagues, he was instrumental in establishing the Drug Discovery Unit at the University of Dundee and he is a member of the Wellcome Centre for Anti-Infectives Research. He is also co-Director of the successful Dundee Proteomics Facility.

Mike was Dean of Research for Life Sciences from 2007-2014 and continues to play a role in Research Strategy. He led the construction of the Discovery Centre for Translational and Interdisciplinary Research and is co-lead on the Growing the Tay Cities BioMedical Cluster component of the Tay Cities Deal. He is Deputy Chair of The Wellcome Trust, a member of the Board of Directors of the Medicines for Malaria Venture (MMV).  He is a Fellow of the Royal Societies of London and Edinburgh, of the Academy of Medical Sciences and a member of EMBO. He was knighted in 2019 for services to science.


Declared Interests as Court member

Declared Interests

Start date on Court

8 November 2021


Senior Lecturer, University of Dundee (2005-current)


Board of Directors, Medicines for Malaria Venture (remunerated)


Other pecuniary interests

Shareholder (minor) in Amphista Therapeutics, a U0D spinout.

Any other disclosure

Chair: Scientific Advisory Group for UK-HSA Covid Antibody Testing


Member: Oversight Group for (Covid) National Core Studies (Chair Patrick Vallance)

Related parties


Register Last Updated




Insect-transmitted protozoan parasites cause widespread and debilitating diseases in man and domestic livestock throughout the tropics. Examples of diseases caused by trypanosomatid parasites include African sleeping sickness (caused by Trypanosoma brucei and transmitted by tsetse flies), Chagas disease (caused by Trypanosoma cruzi) and kala-azar, espundia and oriental sore (caused by the Leishmania). There are no vaccines against these diseases and most of the available drug treatments are toxic and/or ineffective.

Parasite surface molecules must protect the organisms and enable them to identify, and interact with, cells of both the insect vector and the animal host. Many trypanosomatid parasite surface molecules are either glycosylphosphatidylinositol (GPI) anchored glycoproteins or GPI-related glycolipids (Fig.1).

The parasite GPI biosynthetic pathway, and the pathways that assemble the sugar nucleotides that fuel it and the protein O- and N-glycosylation pathways, are validated targets for the development of new chemotherapeutic agents.

 Our research is multi-disciplinary and involves defining:

  • The "structural repertoire" of the parasite glycoproteins (Figs.1 & 3)
  • The "biosynthetic repertoire" of necessary glycosyltransferases and processing enzymes needed to create the structural repertoire (Fig 2)
  • The "metabolic repertoire" of sugar nucleotides, and their biosynthetic and transporter proteins, needed to fuel the biosynthetic repertoire (Figs.2 & 4)

Fig 3. The structural repertoire of known glycosidic linkages in Trypanosoma brucei These goals involve:

(A) The isolation and analysis of parasite surface molecules and sugar nucleotide metabolites using advanced mass spectrometric methods (1-3).

(B) Bioinformatics, gene-knockout, cell biology and advanced mass spectrometric methods, to identify, localise and study the functions of glycoprotein (GPI anchoring and protein N-glycosylation) glycosyltransferases and sugar nucleotide biosynthetic enzymes (4-13).

 (C) The use of quantitative (eg. SILAC) proteomics (14,15) and phosphoproteomics (16,17) methods to determine organellomes, signalling pathways and to identify the modes of action of drugs developed from phenotypic screens. 

(D) Enzymology to define the properties and substrate specificities of enzymes involved in protein glycosylation, GPI anchor biosynthesis and sugar nucleotide assembly (7-10, 18-21).

(E) Drug Discovery, including X-ray crystallography and molecular modelling of drug target enzymes (7-10, 21,22) (Fig.5) (in collaboration with Bill Hunter, Daan van Aalten and the Structural Genomics Consortium), computational chemistry, high-throughput screening and molecular pharmacology (in collaboration with David Gray) and medicinal chemistry (in collaboration with Ian Gilbert and Paul Wyatt).

We also have ongoing studies on the proteome and phosphoproteome of T.brucei (14-17).

 Our ultimate aim is to discover new anti-parasite therapeutic agents for clinical trials through our unique Drug Discovery Unit (23).


Biomarker Discovery and Diagnostics Development

In addition to our work on parasite glycobiology, we use our expertise in mass spectrometry and proteomics to develop lateral flow diagnostic devices for human and animal trypanosomiasis (24-27).


  1. Ryan, C. M., Mehlert, A., Richardson, J.M., Ferguson, M.A.J.*, Johnson, P.J.* (2011). Chemical structure of Trichomonas vaginalis surface lipoglycan: a role for short galactose (b1-4/3) N-acetylglucosamine repeats in host cell interaction. J. Biol. Chem. 286, 40494-40508. *Joint senior authors.
  2. Mehlert, A., Wormald, M.R. and Ferguson, M.A.J. (2012) Modeling of the N-glycosylated transferrin receptor suggests how transferrin binding can occur within the surface coat ofTrypanosoma brucei. PLoS Pathogens 8, e1002618.
  3. Allen, S., Richardson, J.M., Mehlert, A and Ferguson, M.A.J. (2013) Structure of a complex phosphoglycan epitope from gp72 of Trypanosoma cruzi. J. Biol. Chem. 288, 11093-11105.
  4. Izquierdo, L., Nakanishi, M, Mehlert, A., Machray, G., Barton, G.J. and Ferguson, M.A.J. (2009) Identification of a GPI-anchor modifying β1-3 N-acetylglucosaminyltransferase in Trypanosoma brucei. Mol. Microbiol. 71, 478-491
  5. Izquierdo, L., Schulza, B.L., Rodrigues, J.A., Güther, M.L.S., Proctor, J.B., Barton, G.J., Aebi, M. and Ferguson, M.A.J. (2009) Distinct oligosaccharide donor and peptide acceptor specificities of Trypansosoma brucei oligosaccharyltransferases. EMBO J. 28, 2650-2661.
  6. Güther, M.L.S., Beattie, K., Lamont, D.J., James, J., Prescott, A.R. and Ferguson, M.A.J. (2009) The fate of GPI-less procyclin and characterisation of sialylated non-GPI anchored surface coat molecules of procyclic form Trypanosoma brucei. Eukaryotic Cell, 8, 1407-1417.
  7. Marino, K., Güther, M.L., Wernimont, A., Amani, M., Hui, R. and Ferguson, M.A.J. (2010) Identification, subcellular localization, biochemical properties and high-resolution crystal structure of Trypanosoma brucei UDP-glucose pyrophosphorylase. Glycobiology, 12, 1619-1630.
  8.  Mariño, K.M.L., Güther, M.L., Wernimont, A.K., Hui, R., Ferguson, M.A. (2011) “Characterization, localization, essentiality and high-resolution crystal structure of Glucosamine 6-phosphate N-Acetyltranserase from Trypanosoma brucei”. Eukaryot. Cell 10 (7), 985-997
  9. Keuttel, S., Wadum, M.C.T., Guther, M.L.S., Marino, K., Riemer, C. and Ferguson, M.A.J. (2012) The de novo and salvage pathways of GDP-mannose biosynthesis are both sufficient for the growth of bloodstream form Trypanosoma brucei. Mol. Microbiol. 84, 340-351.
  10. Bandini, G., Mariño,K., Güther, M.L.S., Wernimont,A.K.,  Kuettel, S.,  Qiu, W., Afzal, S., Kelner, A., Hui, R. and Ferguson, M.A.J. (2012) Phosphoglucomutase is absent in Trypanosoma brucei and redundantly substituted by phosphomannomutase and phospho-N-acetylglucosamine mutase. Mol. Microbiol. 85, 513–534.
  11. Damerow, M., Rodrigues, J., Wu, D., Guther, M.L.S., Mehlert, A. and Ferguson, M.A.J. (2014) Identification and Functional Characterization of a highly divergent N-Acetylglucosaminyltransferase I (TbGnTI) in Trypanosoma brucei. J. Biol. Chem. 289, 9328-9339.
  12. Izquierdo, L. Acosta-Serrano, A., Mehlert, A. and Ferguson, M.A.J. (2015) Identification of a glycosylphosphatidylinositol anchor-modifying b1-3 galactosyltransferase in Trypanosoma brucei. Glycobiology 25, 438-447
  13. Damerow, M. Graalfs, F., Guther, M.L., Mehlert,A., Izquierdo, L. and Ferguson, M.A. (2016) "A Gene of the beta3-Glycosyltransferase Family Encodes N-Acetylglucosaminyltransferase II Function in Trypanosoma brucei." J. Biol. Chem. 291(26): 13834-13845
  14. Urbaniak, M., Guther, M.L.S. and Ferguson, M.A.J. (2012) Comparative SILAC proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages. PLoS One 7, e36619
  15. Güther, M.L.S., Urbaniak, M.D., Tavendale, A.  Prescott, A.P. and Ferguson, M.A.J. (2014) A high-confidence glycosome proteome for procyclic form Trypanosoma brucei by epitope-tag organelle enrichment and SILAC proteomics. J. Proteome Res, 13, 2796-2806
  16. Nett, I.R.E., Martin, D.M.A., Miranda-Saavedra, D., Lamont, D.J., Barber, J.D., Mehlert, A. and Ferguson, M.A.J. (2009) The phosphoproteome of bloodstream form Trypanonosoma brucei, causative agent of African Sleeping Sickness. Mol. Cell. Proteomics 8, 1527-1538.
  17. Urbaniak, M.D., Martin, D.M.A. and Ferguson, M.A.J. (2013) Global quantitative SILAC phosphoproteomics reveals differential phosphorylation is widespread between the procyclic and bloodstream form lifecycle stages of Trypanosoma brucei. J. Proteome Res. 12, 22332244.
  18. Sizova, O. V., A. J. Ross, Ivanova, I. A., Borodkin, V. S., Ferguson, M. A. J., Nikolaev, A. V. (2011). "Probing Elongating and Branching beta-d-Galactosyltransferase Activities in Leishmania Parasites by Making Use of Synthetic Phosphoglycans." ACS Chem Biol 6 (6), 648-657
  19.  Urbaniak, M.D., Capes, A.S., Crossman, A., O’Neill, S., Thompson, S., Gilbert, I.H.*, Ferguson, M.A.J.* (2014) Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase. Carbohyd. Res. 387, 54-58. *joint corresponding authors
  20. Capes, A.S., Crossman, A., Urbaniak, M.D., Gilbert, S.H., Ferguson, M.A.J.* and Gilbert I.H.* (2014) Probing the substrate specificity of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase with synthetic substrate analogues. Organic & Biomolecular Chemistry 12, 1919-1934. *joint corresponding authors
  21. Urbaniak, M.D., Collie, I., Fang, W., Aristotelous, T., Eskilsson, S.,  Harrison, J.,  Hopkins-Navratilova, I., Frearson, J.A., van Aalten, D.M.F. and Ferguson, M.A.J. (2013) A novel allosteric inhibitor of the uridine diphosphate N-acetylglucosamine pyrophosphorylase from Trypanosoma brucei. ACS Chemical Biology, 8, 1981-1987.
  22. Frearson, J.F., Brand,S., McElroy, S.P., Cleghorn, L.A.T., Smid, O., Stojanovski, L., Price, H.P., Guther, M.L.S., Torrie, L.S., Robinson, D.A., Hallyburton, I., Mpamhanga, C.P. Brannigan, J.A. Wilkinson, A.J., Hodgkinson, M. Hui, R., Qui, W. Raimi, O.G. van Aalten, D.M.F., Brenk, R., Gilbert, I.H., Read, K.D., Fairlamb, A.H.Ferguson, M.A.J., Smith, D.F. and Wyatt, P.G (2010) N-Myristoyltransferase inhibitors: new leads for the treatment of human African trypanosomiasis. Nature 464, 728-732
  23. Field, M.C., Horn, D., Fairlamb, A.H., Ferguson, M.A., Gray, D.W., Read, K.D., DeRycker, M., Torrie, L., Wyatt, P.G., Wyllie, S. and Gilbert, I.H. (2017) "Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need." Nat. Rev. Microbiol. 15(4): 217-231
  24. Sullivan, L., Wall, S., Carrington, M. and Ferguson, M.A.J. (2013) Proteomic selection of immunodiagnostic antigens for human African trypanosomiasis and generation of a prototype lateral flow immunodiagnostic device. PLoS Neglected Tropical Diseases 7, e2087
  25. Fleming, J.R., Sastry, L., Crozier, T.W.M., Napier, G.B., Sullivan, L. and Ferguson, M.A.J. (2014) Proteomic selection of immunodiagnostic antigens for Trypanosoma congolense. PLoS Neglected Tropical Disease, in press
  26. Sullivan, L., Fleming, J. Sastry, L.  Mehlert, A., Wall, S.J. and Ferguson, M.A.J. (2014) Identification of sVSG117 as an immunodiagnostic antigen and evaluation of a dual-antigen lateral flow test for the diagnosis of human African trypanosomiasis. PLoS Neglected Tropical Disease 8, e2976
  27. Sternberg, J.M., Gierliński , M., Biéler, S., Ferguson, M.A.J. and Ndung'u, J.M. (2014) Evaluation of the diagnostic accuracy of prototype rapid tests for human African trypanosomiasis​. PLoS Neglected Tropical Disease e3373